Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aim: G‐protein coupled receptor agonists are currently under investigation for their potential utility in patients with type 2 diabetes mellitus (T2DM). The objective was to determine the pharmacokinetics, pharmacodynamics, safety and tolerability of GPR119 agonist, JNJ‐38431055 in T2DM subjects. Methods: This was a randomized, double‐blind, placebo‐ and positive‐controled, single‐dose cross‐over study and a randomized, double‐blind, placebo‐controled multiple‐dose parallel design study. The study was conducted at 4 US research centres. Two different experiments involving 25 and 32 different subjects were performed in male and female subjects, aged 25–60 years, mean body mass index between 22 and 39.9 kg/m2 who had T2DM diagnosed 6 months to 10 years before screening. JNJ‐38431055 (100 and 500 mg) or sitagliptin (100 mg) as a single‐dose or JNJ‐38431055 (500 mg) once daily for 14 consecutive days were tested. Effects on stimulated plasma glucose, insulin, C‐peptide and incretin concentrations were pre‐specified outcomes. Results: JNJ‐38431055 was well tolerated and not associated with hypoglycaemia. Plasma systemic exposure of JNJ‐38431055 increased as the dose increased, was approximately two‐fold greater after multiple‐dose administration, and attained steady‐state after approximately 8 days. Compared with placebo, single‐dose administration of oral JNJ‐38431055 decreased glucose excursion during an oral glucose tolerance test, but multiple‐dose administration did not alter 24‐h weighted mean glucose. Multiple dosing of JNJ‐38431055 increased post‐meal total glucagon‐like peptide 1 and gastric insulinotropic peptide concentrations compared to baseline. Conclusions: These studies provide evidence of limited glucose lowering and incretin activity for JNJ‐38431055 in subjects with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Cited by
Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Furness, J. B., Rivera, L. R., Cho, H.-J., Bravo, D. M., & Callaghan, B. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.180 · Cited by 526
Commensal bacteria make GPCR ligands that mimic human signalling molecules
Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500
Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells
Hodge, D., Glass, L. L., Diakogiannaki, E., Pais, R., Lenaghan, C., Smith, D. M., Wedin, M., Bohlooly-Y, M., Gribble, F. M., & Reimann, F. (2016) · Peptides · doi:10.1016/j.peptides.2015.06.012 · Cited by 99
Metadata
- Authors
- Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Sarich, T. C., & Stein, P. P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-03-14
- Volume
- 14
- Issue
- 8
- Pages
- 709-716
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2028192858
- Cited by
- 110
- References
- 4
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01587.x
- The paper
- Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Sarich, T. C., & Stein, P. P. (2012). Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01587.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.